Those who were RBD IgG+ and/or IgA+ but did not report a COVID-19 diagnosis were included in the category “asymptomatic or not reported.” A small portion (n = 35/2,464; 1.4%) of SARS-CoV-2 RBD IgG–/IgA– participants reported mild, moderate, or severe adverse events associated with prior COVID-19, though we could not confirm these diagnoses. Here, CD79A is linked to COVID-19.